The Level of Glutamate in the Blood of Children with Hemorrhagic Stroke Before and After Citicoline Neuroprotective Therapy
Objective: Stroke in childhood in many developed countries has become one of the most pressing medical and social problems. Timely neuroprotective therapy in acute hemorrhagic stroke, prevents neurologic deficit in adults. The effectiveness of neuroprotective therapy shows the level of metabolites in blood, one of which is glutamate.
Design: Determining the initial level of glutamate and its dynamics in children with hemorrhagic stroke before and after citicoline neuroprotective therapy.
Results: We examined 104 children, aged 0 to 14 years who were diagnosed with hemorrhagic stroke. Average glutamate levels on admission was 8.9 mmol \ l (N = 5,8 mmol \ l). The same level of glutamate was predictive in nature, ie, in excess of glutamate levels over 7.0 mmol \ l resulted in a coma for a degree, and more than 20.0 mmol \ l leads to death. Following the citicoline neuroprotective therapy, which was part of a complex therapy, showed a decrease of glutamate levels in the blood. It was gradual and by 5-6 days, came to the permissible level, after neuroprotective started therapy. Increasing these parameters was observed after 6 hours after treatment citicoline then carried out again after neuroprotective therapy has been falling.
Conclusions: The analysis results of the study reveals the dependence of the nature of the disease and its outcome. Citicoline neuroprotective therapy should be carried out round the clock in a minimal dosage of the drug, keeping the amount of allowable daily dose.